How Sapu Indexed 28 Million PubMed Abstracts to Accelerate Cancer Research with Qdrant

Sapu is an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers. From its San Diego facility, the team is pioneering a nanomedicine pipeline that takes existing FDA-approved drugs and re-engineers them at the nanoscale, making them smaller, more effective, and less toxic. Building on already-approved compounds gives Sapu a stronger and faster path to therapeutic success in an industry where most candidates never reach patients. Behind the lab work sits an AI tooling suite that does the reading, searching, and synthesis that would otherwise take researchers thousands of hours. Sapu’s internal AI platform supports research paper authorship, references standard operating procedures, and lets the team query its document corpus with the precision biotech R&D requires. As the company grew, so did the volume of documents, the variety of use cases, and the demands placed on the underlying retrieval infrastructure.

Source: Qdrant | 2026-05-12